Purpose Of Review: This review aims to discuss the rationale behind the development of percutaneous LAAC devices as a treatment option for atrial fibrillation patients ineligible for long-term anticoagulation. The evolution of LAAC, from early experiences and challenges to risk mitigation and improved devices and techniques, will be examined. Furthermore, the review will explore our current understanding of the potential and limitations of LAAC in stroke prevention.
Recent Findings: Multiple trials confirm LAAC device safety and efficacy for stroke prevention, but peri-device leak and thrombus remain concerns postimplantation. Even small leaks pose increased stroke risk. While guidelines suggest short-term anticoagulation postimplant; real-world data show equivalent efficacy with dual antiplatelet regimen.
Summary: LAAC device design has evolved and now serve as a viable option for stroke prevention in high-risk atrial fibrillation patients, offering protection in the absence of anticoagulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/HCO.0000000000001091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A new horizon in persistent atrial fibrillation ablation? Evaluating selective CFAE ablation guided by fractionation mapping.
J Interv Card Electrophysiol
January 2025
Princess Grace Hospital, Monaco, Monaco.
Investigating the effect of occupational noise exposure in the risk of atrial fibrillation: a case study among Chinese occupational populations.
Int Arch Occup Environ Health
January 2025
Department of Emergency, The First Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang, 11001, China.
Purpose: This study examines the link between high occupational noise exposure and atrial fibrillation (AF), given the limited existing evidence.
Methods: We conducted a cross-sectional study among participants from a large heavy industry enterprise in China. High noise exposure was defined as an equivalent A-weighted sound level (LAeq, 8 h) of ≥ 80 dB(A) during an 8 h workday.
The role of lipoprotein(a) in atrial fibrillation: a systematic review.
Pol Arch Intern Med
January 2025
Introduction: Atrial fibrillation (AF) is the most prevalent form of cardiac arrhythmia worldwide. Early diagnosis and treatment are essential, emphasizing the need to develop novel biomarkers. Lipoprotein(a) [Lp(a)] has recently been widely investigated as a potential risk factor for various cardiovascular conditions, including AF.
View Article and Find Full Text PDFComparative Evaluation of Consumer Wearable Devices for Atrial Fibrillation Detection: Validation Study.
JMIR Form Res
January 2025
Limburg Clinical Research Center/Mobile Health Unit, Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
Background: Consumer-oriented wearable devices (CWDs) such as smartphones and smartwatches have gained prominence for their ability to detect atrial fibrillation (AF) through proprietary algorithms using electrocardiography or photoplethysmography (PPG)-based digital recordings. Despite numerous individual validation studies, a direct comparison of interdevice performance is lacking.
Objective: This study aimed to evaluate and compare the ability of CWDs to distinguish between sinus rhythm and AF.
Excessive Supraventricular Ectopic Activity in Patients With Acute Ischemic Stroke Is Associated With Atrial Fibrillation Detection Within 24 Months After Stroke: A Predefined Analysis of the MonDAFIS Study.
J Am Heart Assoc
January 2025
Center for Stroke Research Berlin Charité-Universitätsmedizin Berlin Berlin Germany.
Background: Excessive supraventricular ectopic activity (ESVEA) is regarded as a risk marker for later atrial fibrillation (AF) detection.
Methods And Results: The investigator-initiated, prospective, open, multicenter MonDAFIS (Impact of Standardized Monitoring for Detection of Atrial Fibrillation in Ischemic Stroke) study randomized 3465 patients with acute ischemic stroke without known AF 1:1 to usual diagnostic procedures for AF detection or additive Holter monitoring in hospital for up to 7 days, analyzed in a core laboratory. Secondary study objectives include the comparison of recurrent stroke, myocardial infarction, major bleeding, and all-cause death within 24 months in patients with ESVEA (defined as ectopic supraventricular beats ≥480/day or atrial runs of 10-29 seconds or both) versus patients with newly diagnosed AF versus patients without ESVEA or AF (non-ESVEA/AF), randomized to the intervention group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!